Clinical Trial Update: Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in [Phase 2]

View source ↗

Summary

Phase II safety run-in for 177Lu-DOTATATE in metastatic nasopharyngeal cancer is being studied; results not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Metastatic Nasopharyngeal Cancer | Phase 2 | Status: UNKNOWN